1. Home
  2. PARK vs ACET Comparison

PARK vs ACET Comparison

Compare PARK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PARK

Park Dental Partners Inc.

N/A

Current Price

$15.50

Market Cap

61.5M

Sector

Health Care

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.19

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
ACET
Founded
1972
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.5M
71.3M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
PARK
ACET
Price
$15.50
$8.19
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$96.67
AVG Volume (30 Days)
57.9K
199.8K
Earning Date
02-08-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
3.18
N/A
EPS
2.91
N/A
Revenue
$240,209,000.00
N/A
Revenue This Year
$7.62
N/A
Revenue Next Year
$5.75
N/A
P/E Ratio
$5.21
N/A
Revenue Growth
7.47
N/A
52 Week Low
$9.53
$7.15
52 Week High
$17.84
$17.44

Technical Indicators

Market Signals
Indicator
PARK
ACET
Relative Strength Index (RSI) N/A 79.68
Support Level N/A $7.70
Resistance Level N/A $8.56
Average True Range (ATR) 0.00 0.50
MACD 0.00 0.08
Stochastic Oscillator 0.00 90.54

Price Performance

Historical Comparison
PARK
ACET

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: